Abstract
COVID-19 poses a significant burden to populations worldwide. Although the pandemic has accelerated digital transformation, little is known about the influence of digitalization on pandemic developments. Therefore, this country-level study aims to explore the impact of digital adoption on COVID-19 outcomes and government measures. Using the Digital Adoption Index (DAI), we examined the association between countries’ digital preparedness levels and COVID-19 cases, deaths, and stringency indices (SI) of government measures during the early phase of the pandemic. Gradient Tree Boosting pinpointed essential features related to COVID-19 trends, such as digital adoption, populations’ smoker fraction, age, and poverty. Subsequently, regression analyses indicated that higher DAI was associated with significant declines in new cases (β=-362.25/pm; p<0.001) and attributed deaths (β=-5.53/pm; p<0.001) months after the peak. When plotting DAI against the SI normalized for the starting day, countries with higher DAI adopted slightly more stringent government measures (β=4.86; p<0.01). Finally, a scoping review identified 70 publications providing valuable arguments for our findings. Digital adoption shows a positive trend in handling the current pandemic and facilitates the implementation of more decisive governmental measures. Improving the distribution of digital adoption may have the potential to attenuate the impact of COVID-19 cases and deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been funded by the German Federal Ministry of Education and Research (BMBF, grant no.: 01GP1910A).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 4 has been revised and the abstract and discussion updated accordingly.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
